Background Bladder cancer (BCa) can be divided into muscle‐invasive BCa (MIBC) and non−muscle‐invasive BCa (NMIBC). Whether the tumor infiltrates the detrusor muscle is a critical determinant of disease management in patients with BCa. However, the current preoperative diagnostic accuracy of muscular invasiveness is less than satisfactory. The authors report a radiomic‐clinical nomogram for the individualized preoperative differentiation of MIBC from NMIBC. Methods In total, 2602 radiomics...
Fri Aug 30, 2019 16:10
Background Mutations in human epidermal growth factor receptor 2 (HER2; also known as ERBB2) are found in approximately 2% of lung adenocarcinomas. The frequency and clinical course of brain metastases in this oncogenic subset are ill defined. Methods Baseline and subsequent development of brain metastases was evaluated in consecutive patients with HER2‐mutant (n = 98), epidermal growth factor receptor (EGFR)–mutant (n = 200), and KRAS‐mutant lung cancers (n = 200). Results At metastatic...
Fri Aug 30, 2019 16:10
Background Patients with non‐Hodgkin lymphoma (NHL) have an increased risk of venous thromboembolism (VTE), particularly when they are receiving treatment. Blood or marrow transplantation (BMT) is recommended for relapsed/refractory NHL, and the risk of VTE after these patients undergo BMT is uncertain. Methods Patients with NHL who survived 2 years or longer after BMT were surveyed for long‐term health outcomes, including VTE. The median follow‐up was 8.1 years (interquartile range, 5.6‐12.9 years)....
Fri Aug 30, 2019 16:09
British Journal of Cancer, Published online: 02 September 2019; doi:10.1038/s41416-019-0562-yAntihypertensive drugs and pancreatic cancer risk in patients with chronic pancreatitis: a Danish nationwide population-based cohort study
03:00
British Journal of Cancer, Published online: 02 September 2019; doi:10.1038/s41416-019-0560-0CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer
03:00
British Journal of Cancer, Published online: 02 September 2019; doi:10.1038/s41416-019-0557-8Tyrosine kinase inhibition to improve anthracycline-based chemotherapy efficacy in T-cell lymphoma
03:00
01:27
Publication date: Available online 30 August 2019Source: Cancer/RadiothérapieAuthor(s): R. Dendale, J. Thariat, J. Doyen, J. Balosso, D. Stefan, S. Bolle, L. Feuvret, P. Poortmans, J.-M. Hannoun-Lévi, P.-Y. Bondiau, M. Micaud, C. Alapetite, V. Calugaru, J.-L. Habrand, M.-A. MahéRésuméIl existe plus de 100 centres de proton thérapie dans le monde, et trois en France. La protonthérapie française est en phase de structuration et de montée en charge, avec l’ouverture récente des centres de Nice (2016)...
Sat Aug 31, 2019 17:03
Publication date: Available online 30 August 2019Source: Cancer/RadiothérapieAuthor(s): G. Noel, A. Keller, D. AntoniRésuméLa radiothérapie en conditions stéréotaxiques des métastases cérébrales est un traitement reconnu comme efficace, bien toléré, applicable pour des indications thérapeutiques codifiées et validées par les référentiels nationaux et internationaux. Cependant l’efficacité de cette irradiation, l’évolution de la prise en charge des patients et les progrès techniques permettant sa...
Sat Aug 31, 2019 17:03
Cancers, Vol. 11, Pages 1288: FAK-Copy-Gain Is a Predictive Marker for Sensitivity to FAK Inhibition in Breast Cancer Cancers doi: 10.3390/cancers11091288 Authors: Young-Ho Kim Hyun-Kyoung Kim Hee Yeon Kim HyeRan Gawk Seung-Hyun Bae Hye Won Sim Eun-Kyung Kang Ju-Young Seoh Hyonchol Jang Kyeong-Man Hong Background: Cancers with copy-gain drug-target genes are excellent candidates for targeted therapy. In order to search for new predictive marker genes, we investigated...
03:00
Cancers, Vol. 11, Pages 1287: Influence of Cell Type and Culture Medium on Determining Cancer Selectivity of Cold Atmospheric Plasma Treatment Cancers doi: 10.3390/cancers11091287 Authors: Biscop Lin Boxem Loenhout Backer Deben Dewilde Smits Bogaerts Increasing the selectivity of cancer treatments is attractive, as it has the potential to reduce side-effects of therapy. Cold atmospheric plasma (CAP) is a novel cancer treatment that disrupts the intracellular...
Sun Sep 01, 2019 03:00
Cancers, Vol. 11, Pages 1286: Near-Infrared Fluorescent Sorbitol Probe for Targeted Photothermal Cancer Therapy Cancers doi: 10.3390/cancers11091286 Authors: Lee Jung Jo Yang Koh Hyun Abstract: Photothermal therapy (PTT) using a near-infrared (NIR) heptamethine cyanine fluorophore has emerged as an alternative strategy for targeted cancer therapy. NIR fluorophores showing a high molar extinction coefficient and low fluorescence quantum yield have considerable potential...
Sun Sep 01, 2019 03:00
Cancers, Vol. 11, Pages 1285: KCa3.1 Channels Confer Radioresistance to Breast Cancer Cells Cancers doi: 10.3390/cancers11091285 Authors: Mohr Gross Sezgin Steudel Ruth Huber Lukowski KCa3.1 K+ channels reportedly contribute to the proliferation of breast tumor cells and may serve pro-tumor functions in the microenvironment. The putative interaction of KCa3.1 with major anti-cancer treatment strategies, which are based on cytotoxic drugs or radiotherapy, remains...
Sun Sep 01, 2019 03:00
Cancers, Vol. 11, Pages 1282: Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture Cancers doi: 10.3390/cancers11091282 Authors: Clément Bailly Caroline Bodet-Milin Mickaël Bourgeois Sébastien Gouard Catherine Ansquer Matthieu Barbaud Jean-Charles Sébille Michel Chérel Françoise Kraeber-Bodéré Thomas Carlier Personalized medicine represents a major goal in oncology. It has its underpinning in the identification of biomarkers with diagnostic, prognostic,...
Sat Aug 31, 2019 03:00
Cancers, Vol. 11, Pages 1283: Unique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy Targets Cancers doi: 10.3390/cancers11091283 Authors: Jason Roszik Abir Khan Anthony P. Conley J. Andrew Livingston Roman Groisberg Vinod Ravi Roberto Carmagnani Pestana Shiraj Sen Vivek Subbiah Intimal sarcomas are rare and histologically heterogeneous tumors, commonly arising from the pulmonary arteries. They have remained challenging...
Sat Aug 31, 2019 03:00
Cancers, Vol. 11, Pages 1284: Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature Cancers doi: 10.3390/cancers11091284 Authors: Guerini Triggiani Maddalo Bonù Frassine Baiguini Alghisi Tomasini Borghetti Pasinetti Bresciani Magrini Buglione Anticancer treatment efficacy is limited by the development of refractory tumor cells characterized by increased expression and activity of mechanisms...
Sat Aug 31, 2019 03:00
Cancers, Vol. 11, Pages 1281: Analysing Tumour Growth Delay Data from Animal Irradiation Experiments with Deviations from the Prescribed Dose Cancers doi: 10.3390/cancers11091281 Authors: Leonhard Karsch Elke Beyreuther Doreen Eger Passos Jörg Pawelke Steffen Löck The development of new radiotherapy technologies is a long-term process, which requires proof of the general concept. However, clinical requirements with respect to beam quality and controlled dose delivery may...
Sat Aug 31, 2019 03:00
Cancers, Vol. 11, Pages 1280: STAT3, a Master Regulator of Anti-Tumor Immune Response Cancers doi: 10.3390/cancers11091280 Authors: Rébé Ghiringhelli Immune cells in the tumor microenvironment regulate cancer growth. Thus cancer progression is dependent on the activation or repression of transcription programs involved in the proliferation/activation of lymphoid and myeloid cells. One of the main transcription factors involved in many of these pathways is the signal transducer and...
Fri Aug 30, 2019 03:00
Cancers, Vol. 11, Pages 1278: Increased Non-Homologous End Joining Makes DNA-PK a Promising Target for Therapeutic Intervention in Uveal Melanoma Cancers doi: 10.3390/cancers11091278 Authors: Doherty Bryant Valluru Rennie Sisley Uveal melanoma (UM) is the most common primary intraocular tumour in adults, with a mean survival of six months following metastasis. The survival rates have not improved in over 30 years. This study has shown that sister chromatid exchange (SCE)...
Fri Aug 30, 2019 03:00
Cancers, Vol. 11, Pages 1279: Ultra-Mutation in IDH Wild-Type Glioblastomas of Patients Younger than 55 Years is Associated with Defective Mismatch Repair, Microsatellite Instability, and Giant Cell Enrichment Cancers doi: 10.3390/cancers11091279 Authors: Barresi Simbolo Mafficini Piredda Caffo Cardali Germanò Cingarlini Ghimenton Scarpa Background: Glioblastomas (GBMs) are classified into isocitrate dehydrogenase (IDH) mutants and IDH wild-types...
Fri Aug 30, 2019 03:00
Cancers, Vol. 11, Pages 1276: Extracellular Vesicles from Human Advanced-Stage Prostate Cancer Cells Modify the Inflammatory Response of Microenvironment-Residing Cells Cancers doi: 10.3390/cancers11091276 Authors: Letizia Mezzasoma Egidia Costanzi Paolo Scarpelli Vincenzo Nicola Talesa Ilaria Bellezza Prostate cancer (PCa) progression is strictly associated with microenvironmental conditions, which can be modified by cancer-released extracellular vesicles (EVs), important...
Fri Aug 30, 2019 03:00
Cancers, Vol. 11, Pages 1275: High Proportion of Potential Candidates for Immunotherapy in a Chilean Cohort of Gastric Cancer Patients: Results of the FORCE1 Study Cancers doi: 10.3390/cancers11091275 Authors: Miguel Cordova-Delgado Mauricio P. Pinto Ignacio N. Retamal Matías Muñoz-Medel María Loreto Bravo María F. Fernández Betzabé Cisternas Sebastián Mondaca César Sanchez Hector Galindo Bruno Nervi Carolina Ibáñez Francisco Acevedo Jorge Madrid José...
Fri Aug 30, 2019 03:00
Cancers, Vol. 11, Pages 1277: Long Pentraxin-3 Follows and Modulates Bladder Cancer Progression Cancers doi: 10.3390/cancers11091277 Authors: Sara Matarazzo Laura Melocchi Sara Rezzola Elisabetta Grillo Federica Maccarinelli Arianna Giacomini Marta Turati Sara Taranto Luca Zammataro Marianna Cerasuolo Mattia Bugatti William Vermi Marco Presta Roberto Ronca Bladder tumors are a diffuse type of cancer. Long pentraxin-3 (PTX3) is a component of the...
Fri Aug 30, 2019 03:00
Cancers, Vol. 11, Pages 1274: Detection of Clinical Mesenchymal Cancer Cells from Bladder Wash Urine for Real-Time Detection and Prognosis Cancers doi: 10.3390/cancers11091274 Authors: Bee Luan Khoo Charlotte Bouquerel Pradeep Durai Sarannya Anil Benjamin Goh Bingcheng Wu Lata Raman Ratha Mahendran Thomas Thamboo Edmund Chiong Chwee Teck Lim Bladder cancer (BC) is a disease that requires lifelong surveillance due to its high recurrence rate. An efficient...
Fri Aug 30, 2019 03:00
Cancers, Vol. 11, Pages 1273: Etiology-Specific Analysis of Hepatocellular Carcinoma Transcriptome Reveals Genetic Dysregulation in Pathways Implicated in Immunotherapy Efficacy Cancers doi: 10.3390/cancers11091273 Authors: Wei Tse Li Angela E. Zou Christine O. Honda Hao Zheng Xiao Qi Wang Tatiana Kisseleva Eric Y. Chang Weg M. Ongkeko Immunotherapy has emerged in recent years as arguably the most effective treatment for advanced hepatocellular carcinoma (HCC), but...
Fri Aug 30, 2019 03:00
Abstract Purpose Circulating tumour cells (CTCs) are a marker of poor prognosis and are associated with increased risk of venous thromboembolism in metastatic breast cancer (MBC). We aimed to determine if the presence of CTCs and plasma markers of hypercoagulability [thrombin–antithrombin III (TAT), fibrinogen and d-dimer] are biomarkers of survival in MBC. Methods/patients ...
Sat Aug 31, 2019 03:00
Abstract As the research into the organic anion transporting polypeptides (OATPs) continues to grow, it is important to ensure that the data generated is accurate and reproducible. In the in vitro evaluation of OATP1B1/1B3 inhibition, there are many variables that can contribute to variability in the resulting inhibition constants which can then, in turn, contribute to variable results when clinical predictions (R‐values) are performed. Currently, the only experimental condition recommended by the...
Thu Aug 29, 2019 17:44
Purpose: The use of VEGFR TKIs for the adjuvant treatment of renal cell carcinoma (RCC) remains controversial. We investigated the effects of adjuvant VEGFR TKIs on circulating cytokines in the ECOG-ACRIN 2805 (ASSURE) trial.Experimental Design: Patients with resected high-risk RCC were randomized to sunitinib, sorafenib, or placebo. Plasma from 413 patients was analyzed from post-nephrectomy baseline, 4 weeks, and 6 weeks after treatment initiation. Mixed effects and Cox proportional hazards models...
Fri Aug 30, 2019 17:46
Purpose: HER3 is a compelling target for cancer treatment; however no HER3-targeted therapy is currently clinically available. Here, we produced U3-1402, an anti-HER3 antibody-drug conjugate with a topoisomerase I inhibitor exatecan -derivative (DXd), and systematically investigated its targeted drug delivery potential and antitumor activity in preclinical models. Experimental Design: In vitro pharmacological activities and the mechanisms of action of U3-1402 were assessed in several human cancer...
Fri Aug 30, 2019 17:45
Purpose: We recently reported that indoleamine 2, 3-dioxygenase (IDO) activity is inversely related to distant metastasis risk and survival in stage III non-small cell lung cancer (NSCLC). The present study examined whether radiotherapy (RT) dose fractionation correlates with IDO-mediated immune activity in patients with early-stage NSCLC. Methods: Patients with newly diagnosed stage I-II NSCLC treated with either conventionally fractionated 3-dimensional conformal radiotherapy (3DCRT) or stereotactic...
Fri Aug 30, 2019 17:45
Purpose:In patients with >1 non-small cell lung carcinoma (NSCLC), the distinction between separate primary lung carcinomas (SPLCs) and intrapulmonary metastases (IPMs) is a common diagnostic dilemma with critical staging implications. Here, we compared the performance of comprehensive next-generation sequencing (NGS) to standard histopathologic approaches for distinguishing NSCLC clonal relationships in clinical practice. Experimental Design:We queried 4119 NSCLCs analyzed by 341-468 gene MSK-IMPACT...
Fri Aug 30, 2019 17:45
Purpose: To test inhibition of enhancer of zeste homolog 2 (EZH2) activity for cancer therapy. Experimental Design: This phase 1 study determined the safety, maximum tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of the intravenously administered, highly selective EZH2 inhibitor, GSK2816126, (NCT02082977).Doses of GSK2816126 ranged from 50-3000 mg twice weekly, and GSK2816126 was given 3-weeks-on/1-week-off in 28-day cycles. Eligible patients had solid tumors or B-cell lymphomas...
Fri Aug 30, 2019 17:45
Purpose: Polyclonal emergence of KIT secondary mutations is a main mechanism of imatinib progression in gastrointestinal stromal tumor (GIST). Approved KIT inhibitors sunitinib and regorafenib have complementary activity against KIT resistance mutations. Preclinical evidence suggests that rapid alternation of sunitinib and regorafenib broadens the spectrum of imatinib-resistant subclones targeted. Experimental Design: Phase Ib study investigating continuous treatment with cycles of sunitinib (three...
Fri Aug 30, 2019 17:45
Publication date: Available online 31 August 2019Source: Critical Reviews in Oncology/HematologyAuthor(s): Eliana Ivaldi, Dalila Di Mario, Alberto Paderno, Cesare Piazza, Paolo Bossi, Nicola Alessandro Iacovelli, Fabiola Incandela, Laura Locati, Carlo Fallai, Ester OrlandiAbstractEarly stage (T1-2, N0-1) oral squamous cell carcinoma (OSCC) has a generally favorable prognostic outcome. However, locoregional recurrences can occur in up to 30-35% of patients, and 20% will eventually die of disease....
Sun Sep 01, 2019 14:42
Publication date: Available online 31 August 2019Source: Critical Reviews in Oncology/HematologyAuthor(s): Diane Pannier, Abel Cordoba, Thomas Ryckewaert, Yves-Marie Robin, Nicolas PenelAbstractWe review the role of hormonal therapy in the management of different conjunctive tumors. Progestin and aromatase inhibitors seem active in low-grade endometrial stromal sarcoma, but larger case-series are needed. There is no evidence to support the use of hormonal therapy as an adjuvant treatment for low-grade...
Sun Sep 01, 2019 14:42
Publication date: October 2019Source: European Journal of Cancer, Volume 120Author(s): Peter Hohenberger, Sylvie Bonvalot, Frits van Coevorden, Pjotr Rutkowski, Eberhard Stoeckle, Christine Olungu, Saskia Litiere, Eva Wardelmann, Alessandro Gronchi, Paolo CasaliAbstractBackgroundEORTC (European Organisation of Research and Treatment of Cancer) 62024 is a phase III randomised trial evaluating adjuvant imatinib in patients with gastrointestinal stromal tumours (GISTs) and no evidence of residual disease...
Sun Sep 01, 2019 16:23
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου